FRIDAY, Oct. 12 (HealthDay News) -- Autism researchers have been
given the go-ahead by the U.S. Food and Drug Administration to
launch a small study in children with autism that evaluates whether
a child's own umbilical cord blood may be an effective
Thirty children with the disorder, aged 2 to 7, will receive
injections of their own stem cells from umbilical cord blood banked
by their parents after their births. All of the cord blood comes
from the Cord Blood Registry, the world's largest stem cell
Scientists at Sutter Neuroscience Institute, in Sacramento,
Calif., said the placebo-controlled study will evaluate whether the
stem cell therapy helps improve language and behavior in the
There is anecdotal evidence that stem cell infusions may have a
benefit in other conditions such as cerebral palsy, said lead study
investigator Dr. Michael Chez, director of pediatric neurology at
"We're hoping we'll see in the autism population a group of patients that also responds," Chez said. Other autism and stem cell research is going on abroad, but this study is the first to use a child's own cord blood stem cells.
Chez said the study will involve only patients whose autism is
not linked to a genetic syndrome or brain injury, and all of the
children will eventually receive the stem cells.
Two infusions will take place during the 13-month study. At the
start of the research, the children will be split into two groups,
half receiving an infusion of cord blood stem cells and half
receiving a placebo. At six months, the groups will swap therapies.
The infusions will be conducted on an outpatient basis with close
monitoring, Chez said.
"We're working with Sutter Children's Hospital, who does our oncology infusions with the same-age children," he said. "They are very experienced nurses who work with preschool and school-age kids to help them get through medical experiences."
Each child and his or her parents will be given a private room
with a television and videos, beverages, and perhaps a visit from
the hospital's canine therapy dog, and then a topical anesthetic
will be applied to the arm to numb the skin before intravenous
needle placement. A hematology expert will be giving the infusions
and monitoring for safety, said Chez, who noted that each child
will be watched closely for an hour and a half before heading home.
They will be seen the next day as well for a safety check.
At six, 12 and 24 weeks, the researchers will measure behavioral
and language changes in the children, and other changes noted by
parents and the children's doctors will be logged as well.
"Parental observations like socialization and irritability scale as secondary measures are important," Chez said. Brain electrical activity and immune markers such as levels of pro-inflammatory proteins in the blood also will be tracked.
The FDA-approved study is being funded by a grant from the Cord
Blood Registry Corporation, but they are not involved in the
hands-on research, Chez said. The Sutter Institute for Medical
Research is supporting the research with supplies and staff as
well, he added.
One in 88 children -- about five times as many boys as girls --
are diagnosed with autism, according to the U.S. Centers for
Disease Control and Prevention. But its cause is unknown and there
is no cure for the disorder, which begins in early childhood and
affects social, behavioral and language development.
Genetics and environmental and immunological factors are thought
to play a role, and possibly the interaction of these and other
variables, Chez said. He pointed out that autism is not actually
one disorder, but stretches across a spectrum in which some
children have more severe symptoms than others. One theory suggests
autism occurs because cells in the brain, called neurons, are not
connecting normally. Chez said stem cells may address this
Chez is particularly interested in the relationship between the
nervous and immune systems, and said stem cells from cord blood
have been used to treat some cancers and immune disorders. In some
children with autism, spinal fluid tests and brain tests have
indicated that immune problems exist, and, he said, "We hope this
therapy may correct some of those deficiencies."
Dr. Andrew Adesman, chief of developmental and behavioral
pediatrics at Steven and Alexandra Cohen Children's Medical Center
of New York, said this is a well-designed preliminary study looking
at whether or not cord blood can be helpful. Adesman was not
involved in the study.
"There are mixed opinions about this approach," Adesman said. "A lot of research suggests that there may be an immunological component involved in autism, but some are skeptical this specific approach will be effective. If nothing else, this study is designed such that we should have preliminary results in about a year's time."
Even if the results are positive, he said, it could take a while
before the general population has access to treatments.
"The media often trumpets new findings that are hopeful, but obviously there can be significant time before research translates to the bedside. Not every finding is applicable to all patients," he said. "There are elements of premature hope in many stories."
Chez also cautioned that this is very early research.
"You can't rush good science," he said. "We don't want to give people false hope. Part of doing this is to decide whether we should be doing this."
The U.S. National Institute of Child Health and Human
Development has more about
Please be aware that this information is provided to supplement the care provided by your physician. It is neither intended nor implied to be a substitute for professional medical advice. CALL YOUR HEALTHCARE PROVIDER IMMEDIATELY IF YOU THINK YOU MAY HAVE A MEDICAL EMERGENCY. Always seek the advice of your physician or other qualified health provider prior to starting any new treatment or with any questions you may have regarding a medical condition.
Copyright © EBSCO Publishing. All rights reserved.